Target intelligence / Profile preview

Sodium-dependent glucose cotransporter 2 (SGLT2)

Target
SGLT2
Molecular classification
Sodium glucose cotransporter family, SLC5 (solute carrier 5) family, Symporter, Transporter
01

Overview

Sodium-dependent glucose cotransporter 2 (SGLT2) is a protein encoded by the SLC5A2 gene. It is the major cotransporter involved in glucose reabsorption in the kidney, specifically located in the early proximal tubule (S1 and S2 segments). It is responsible for reabsorbing approximately 80-90% (or up to 97%) of the glucose filtered by the kidney glomerulus. SGLT2 is a symporter belonging to the SLC5 family, utilizing the energy from the sodium gradient created by the Na+/K+ ATPase to transport glucose into the cell, even against its concentration gradient. The protein consists of approximately 670 amino acids organized in 14 transmembrane helices. While predominantly expressed in the renal cortex, it has also been found in other tissues including mammary glands, testis, liver, lungs, intestines, skeletal muscles, spleen, and cerebellum.

Other names
SLC5A2
02

Mechanism of action

SGLT2 inhibitors prevent the kidneys' reuptake of glucose from the glomerular filtrate by inhibiting the SGLT2 transporter in the proximal tubule. This leads to increased urinary glucose excretion and consequently lowers blood glucose levels. This mechanism is insulin-independent.

03

Biological functions

Active transport glucose reabsorption in the kidneyReabsorption of approximately 80-90% (up to 97%) of glucose filtered by the kidney glomerulusSecondary active transport (co-transport) of glucose using sodium gradientTransport of glucose against its concentration gradientSodium-to-glucose coupling ratio of 1:1
04

Disease associations

Significant role in type 2 diabetes mellitus (overexpression contributes to hyperglycemia)Potential role in cancer (expressed in various tumor cells)
05

Safety considerations

Rare cases of diabetic ketoacidosis (DKA), including atypical cases without severe hyperglycemiaRegulatory recommendations (EMA, FDA) to minimize DKA risk
06

Interacting drugs

Canagliflozin

5 more in the full profile.

Beyond the preview

Go deeper on Sodium-dependent glucose cotransporter 2 (SGLT2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sodium-dependent glucose cotransporter 2 (SGLT2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call